This $2 billion unicorn startup is corporate America's secret weapon against Ozempic
Briefly

"Because Ozempic and other GLP-1s were primarily created to treat diabetes (before being prescribed for weight loss in an off-label capacity), the company has significant experience observing how the medication worked on patients before demand drastically expanded over the past year."
Read at www.fastcompany.com
[
add
]
[
|
|
]